Turn Therapeutics Inc (TTRX)
NASDAQ:TTRX
Want to see TTRX full AI Analyst Report?
Top Page
Turn Therapeutics Inc
(NASDAQ:TTRX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$5.50
▲(100.73% Upside)
Action:Reiterated
Date:06/03/26
Score is held down primarily by weak financial performance (no revenue, ongoing losses, and worsening 2025 cash burn despite improved equity and low debt). Technicals are supportive with strong momentum, but overbought signals add short-term risk. Corporate events are a notable positive due to interim Phase 2 updates and financing/runway extension, while valuation remains constrained by negative earnings and no dividend.
Positive Factors
Phase 2 interim GX-03 efficacy and safety
Robust interim efficacy and clean safety in the Phase 2 cohort materially de-risks the lead program over the coming 2–6 months. Durable clinical signal and tolerability improve prospects for regulatory discussions, partner interest, and smoother transition to larger registrational studies if maintained.
Negative Factors
Pre-revenue with persistent losses
The company remains pre-revenue and loss-making, requiring continual external financing to sustain operations. This structural profile increases funding dependence, heightens dilution risk, and constrains ability to invest across programs unless clinical results rapidly convert into higher-probability commercial outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 2 interim GX-03 efficacy and safety
Robust interim efficacy and clean safety in the Phase 2 cohort materially de-risks the lead program over the coming 2–6 months. Durable clinical signal and tolerability improve prospects for regulatory discussions, partner interest, and smoother transition to larger registrational studies if maintained.
Read all positive factors
Turn Therapeutics Inc (TTRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$178.43M
Dividend YieldN/A
Average Volume (3M)2.86M
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,788,040
10 Day Avg. Volume2,856,380
30 Day Avg. Volume2,856,380
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)11.55
Price to Sales (P/S)0.00
P/FCF Ratio-19.94
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.12K
Enterprise Value/Ebitda-45.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Turn Therapeutics Inc Business Overview & Revenue Model
Company Description
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery syste...
How the Company Makes Money
null...
Turn Therapeutics Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| EBITDA | -3.14M | -1.72M | -2.25M |
| Net Income | -3.19M | -1.77M | -2.29M |
Balance Sheet | |||
| Total Assets | 12.16M | 2.05M | 2.01M |
| Cash, Cash Equivalents and Short-Term Investments | 5.08M | 872.60K | 1.18M |
| Total Debt | 80.38K | 121.04K | 25.16K |
| Total Liabilities | 7.48M | 2.23M | 1.93M |
| Stockholders Equity | 4.69M | -177.43K | 85.77K |
Cash Flow | |||
| Free Cash Flow | -2.72M | -1.46M | -1.42M |
| Operating Cash Flow | -2.56M | -1.36M | -1.38M |
| Investing Cash Flow | -152.99K | -99.47K | -44.31K |
| Financing Cash Flow | 6.92M | 1.15M | 500.00K |
Turn Therapeutics Inc Risk Analysis
Turn Therapeutics Inc disclosed 54 risk factors in its most recent earnings report. Turn Therapeutics Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Turn Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $178.43M | -33.52 | -116.83% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.01M | ― | ― | ― | -1.81% | -217.37% | |
45 Neutral | $4.95M | -0.23 | -203.36% | ― | ― | 93.30% | |
43 Neutral | $10.07M | -0.21 | 261.84% | ― | -35.62% | 70.55% | |
43 Neutral | $5.48M | -1.24 | -79.47% | ― | -100.00% | 62.88% | |
43 Neutral | $3.40M | -0.09 | -215.04% | ― | -100.00% | 89.96% |
* Healthcare Sector Average
TTRX
Turn Therapeutics Inc
6.09
-3.11
-33.80%
AIM
AIM ImmunoTech
0.37
-8.62
-95.84%
SCNI
Scinai Immunotherapeutics
0.27
-2.25
-89.21%
PULM
Pulmatrix
1.53
-5.31
-77.63%
DRMA
Dermata Therapeutics
1.21
-5.05
-80.67%
AZTR
Azitra Inc
0.21
-1.49
-87.63%
Turn Therapeutics Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data
Positive
Jun 3, 2026
On June 1, 2026, Turn Therapeutics released an updated investor presentation ahead of the 2026 Jefferies Global Healthcare Conference, highlighting interim Phase 2 data for its lead atopic dermatitis candidate GX-03 and detailing its broader pipel...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data
Positive
Jun 1, 2026
On June 1, 2026, Turn Therapeutics reported interim results from the first 50 completed subjects in its ongoing randomized, double-blind, vehicle-controlled Phase 2 trial of GX-03 in adults with moderate-to-severe atopic dermatitis. The analysis, ...
Business Operations and StrategyProduct-Related Announcements
Turn Therapeutics highlights GX-03 preclinical data in dermatitis
Positive
May 27, 2026
On May 27, 2026, Turn Therapeutics announced that a peer-reviewed study of its lead candidate GX-03 was published in the Journal of Dermatological Treatment, highlighting the drug’s activity in an IL-36–associated inflammatory model. I...
Business Operations and Strategy
Turn Therapeutics CEO to Present at Jefferies Conference
Neutral
May 19, 2026
On May 19, 2026, Turn Therapeutics Inc. announced that Chief Executive Officer Bradley Burnam will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, from 9:55 a.m. to 10:25 a.m. EDT. The presentation will be webcas...
Business Operations and StrategyExecutive/Board Changes
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03
Positive
May 18, 2026
Turn Therapeutics Inc., a clinical-stage biotechnology company listed on Nasdaq, develops targeted, localized therapies for inflammatory skin diseases with significant unmet medical needs. Its lead investigational therapy, GX-03, is a first-in-cla...
Business Operations and StrategyPrivate Placements and Financing
Turn Therapeutics Secures Growth Capital to Advance Dermatology
Positive
Mar 24, 2026
On March 23, 2026, Turn Therapeutics Inc. entered into a secured growth capital loan facility of up to $25 million with Avenue Venture Opportunities Fund II, L.P., anchored by a $7 million tranche funded at closing and additional tranches tied to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.